SCHEMBL6225672

SCHEMBL6225672

CC(NCc1ccc(N2CCCC2)cc1)c1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.59
▸ KMT2A Q03164 4/20 0.49
▸ MEN1 O00255 3/20 0.49
▸ ALDH1A1 P00352 4/20 0.46
▸ MAPT P10636 3/20 0.46
▸ KCNQ2 O43526 1/20 0.46
▸ CASR P41180 3/20 0.46
▸ CYP3A4 P08684 2/20 0.45
▸ CHRM2 P08172 1/20 0.45
▸ HTR1A P08908 1/20 0.45
▸ ADRA2A P08913 1/20 0.45
▸ ADORA3 P0DMS8 1/20 0.45
▸ CHRM1 P11229 1/20 0.45
▸ SMPD1 P17405 1/20 0.45
▸ DRD1 P21728 1/20 0.45
▸ TBXA2R P21731 1/20 0.45
▸ SLC6A2 P23975 1/20 0.45
▸ SLC6A4 P31645 1/20 0.45
▸ ADRA1A P35348 1/20 0.45
▸ OPRM1 P35372 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3924962 1.00 SMN1; SMN2 (0.59) SMN1; SMN2KMT2AMEN1ALDH1A1MAPT
SCHEMBL14469578 0.82 SMN1; SMN2 (0.82) SMN1; SMN2KMT2AMEN1ALDH1A1CASR
SCHEMBL2238765 0.81 NCF1 (0.51) SMN1; SMN2KMT2AMEN1ALDH1A1MAPT
SCHEMBL79765 0.79 SMN1; SMN2 (0.76) SMN1; SMN2KMT2AMEN1ALDH1A1CASR
SCHEMBL29560 0.79 SMN1; SMN2 (0.76) SMN1; SMN2KMT2AMEN1ALDH1A1CASR
SCHEMBL774613 0.79 SMN1; SMN2 (0.76) SMN1; SMN2KMT2AMEN1ALDH1A1CASR
Hydrochloric Acid SCHEMBL5493749 0.77 SMN1; SMN2 (0.79) SMN1; SMN2KMT2AMEN1ALDH1A1MAPT
SCHEMBL27939948 0.77 SMN1; SMN2 (0.73) SMN1; SMN2KMT2AMEN1ALDH1A1CASR
Hydrochloric Acid SCHEMBL9635019 0.77 SMN1; SMN2 (0.79) SMN1; SMN2KMT2AMEN1ALDH1A1MAPT
Hydrochloric Acid SCHEMBL27830673 0.77 SMN1; SMN2 (0.79) SMN1; SMN2KMT2AMEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1509497-A1 CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES Amgen Inc. (US) 2005-03-02 — — EP disclosed
WO-2003099776-A1 CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES AMGEN INC. (US) 2003-12-04 — — WO disclosed
Send feedback